CoagulationDisorders near Rego Park, NY

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience We are devoted to providing services that are patient centered and compassionate and care for you as a person nbsp;

Biography: Rohit K. Jain MD, MPH is an Associate Professor of Medicine at Weill Cornell Medicine and Attending Physician at NewYork-Presbyterian Hospital- Weill Cornell Medical Center. Dr. Jain earned his medical degree at Topiwala National Medical College and B.Y.L. Nair Charitable Hospital, Mumbai, India. He completed Internal Medicine Residency at Johns Hopkins University/Sinai Hospital of Baltimore and Hematology-Oncology Fellowship at Roswell Park Cancer Institute University at Buffalo, New York. After fellowship, Dr. Jain, joined the H. Lee Moffitt Cancer Center in Tampa, Florida as Assistant Professor, and was instrumental in building the bladder cancer program. Dr. Jain was selected as Castle Connolly "Top Doctor" for 2024, as well as one of America's Best Prostate Cancer Oncologist by Newsweek magazine in 2024. Dr. Jain was recruited to Weill Cornell Medicine (WCM) in 2024. He cares for patients with bladder (urothelial), kidney (renal), prostate and testicular cancers, with a major focus in urothelial cancers. His research interests are primarily in urothelial and prostate cancers. Dr. Jain is involved in biomarker research as well as developing innovative clinical trials for patients, and he has received funding from the National Cancer Institute (NCI).

Care Philosophy: I am dedicated to the surgical and medical management of women's cancer and also committed to advancing clinical and translational research in this field, with a focus on cancer genetics.

Biography: Dr. Lisa Roth is an Assistant Professor in the Departments of Pediatrics and Medicine at Weill Cornell Medicine. She is also the Director of the Adolescent and Young Adult Lymphoma Program at Weill Cornell Medicine/New York Presbyterian Hospital. Dr. Roth has been named the Charles, Lillian, and Betty Neuwirth Clinical Scholar in Pediatric Oncology. Dr. Roth completed her undergraduate work at Duke University. She received her medical degree from New York University School of Medicine. Dr. Roth conducted her residency at NewYork-Presbyterian/Weill Cornell and her fellowship in pediatric hematology/oncology at Memorial Sloan-Kettering Cancer Center and NewYork-Presbyterian where she served as chief fellow. Dr. Roth specializes in treating children, adolescents and young adults with lymphoma and leukemia. She is a member of the Children's Oncology Group and an active participant in Hodgkin lymphoma and non-Hodgkin lymphoma clinical trials. She is also a member of the Weill Cornell Center for Lymphoma, a group which is internationally recognized for it's leadership in the treatment of patients with lymphoma. Dr. Roth's research focuses on identifying new treatments for children with lymphoma. She is particularly interested identifying novel targeted therapies. Targeted therapies may be less toxic than conventional chemotherapy and may be able to rescue those patients with chemotherapy-resistant disease. Dr. Roth has been recognized for her work with awards from the National Institutes of Health (NIH), the Lymphoma Research Foundation, Hyundai Hope on Wheels Foundation, and the St. Baldrick's Foundation. For More Videos, please see below: OR-Live: Treating AYA Patients with Hodgkins Lymphoma (5/10/2017)https://www.youtube.com/watch?v=PT-Qwg2EvqgLymphoma Cancer Treatment NY - Weill Cornell Dr. Roth In the News: Taking Away the Toll (12/2015)http://www.nyrr.org/races-and-events/2016/nyrr-new-york-mini-10k/lisa-roth

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience We are devoted to providing services that are patient centered and compassionate and care for you as a person nbsp;

Care Philosophy: "Better people means better experiences. Our care team is committed to delivering results that change lives."

Biography: Dr. Justin Kaner graduated with a B.S. in Biology from Syracuse University in 2009 where his initial interest in hematologic malignancies developed. He received his M.D. from New York Medical College in 2013 before completing his Internal Medicine Residency at Albert Einstein College of Medicine/Montefiore Medical Center. During residency Dr. Kaner pursued his interest in hematologic malignancies by undertaking several research projects mainly focused on myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) which led to several publications in peer reviewed journals, including Leukemia and Lymphoma and Oncotarget, as well as numerous abstracts presented at the American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH) Annual Meetings. Additionally, Dr. Kaner served as Chief Resident after his residency at Montefiore Medical Center.Throughout his Hematology/Oncology fellowship at Weill Cornell Medicine and NewYork-Presbyterian Hospital, Dr. Kaner worked in the laboratory of Dr. Monica Guzman and with clinical mentorship from Dr. Ellen Ritchie and Dr. Gail Roboz of the Weill Cornell Leukemia Program. During this time, he studied the activity of a novel therapeutic, PU-H71, in PTPN11 mutated AML as well as the prognostic impact of PTPN11 mutations in AML. During his fellowship training Dr. Kaner also developed a particular interest in early phase clinical trials and novel therapeutics for the treatment of Relapsed/Refractory AML. Dr. Kaner accepted an opportunity to remain at Weill Cornell, joining the Leukemia Program to focus on caring for hospitalized patients with various acute and chronic leukemias, MDS and myeloproliferative neoplasms (MPNs).

Care Philosophy: Today's research and treatment of lung cancer are at the cutting edge of science and technology. Enormous progress has been made in lung cancer treatment. Several targeted therapies and now immunotherapies have changed the way we treat the disease. Cancer patients and their families who come to the Lombardi Comprehensive Cancer Center will work closely with a team of dedicated and knowledgeable cancer specialists to determine the most appropriate treatment path for their specific cancer needs. My research is focused on advancing our understanding of lung cancer and thymic tumors and their responses to specific treatment, including how to harness the body's immune system to fight cancer. I keep my patients and their families front and center in my practice to help them understand the technology that may be available to them. My goal is to always work together with my patients, using science to overcome disease.

Biography: Dr. Paul Pagnini has served as a leader in community-based and academic radiation oncology for the past 20 years. Dr. Pagnini completed his residency training in Radiation Oncology at Tufts/New England Medical Center where he was chief resident in his final year. He was awarded the prestigious Research Fellowship Award from the American Society of Therapeutic Radiation Oncology, which enabled him to study the role of intensity modulated radiation therapy (IMRT) for the treatment of cancers of the central nervous system. He has served on the Faculty of the University of Southern California, Keck School of Medicine where he was the Radiation Oncology Residency Program Director. His most recent position was with the Cleveland Clinic Florida, where he served as Department Chair for the last five years. He has multiple peer reviewed publications in the areas of intensity modulated radiation therapy (IMRT), 3-D conformal radiation therapy, Cyberknife, and Gamma-Knife radiosurgery.